Issue No. 40

Updated Perinatal Guidelines Now Available

The Public Health Service Task Force "Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States" has been revised to include:

• Updates to Clinical Scenario #3. The new information discusses a 3 to 7 day “tail” of postpartum maternal ZDV/3TC following single dose maternal/infant nevirapine; this “tail” may reduce the risk of nevirapine resistance.
• Updated information on the role of cesarean delivery in preventing mother-to-child transmission of HIV.
• An updated Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy, including a new section on tipranavir.
• A Perinatal Antiretroviral Guidelines Working Group Conflict of Interest Disclosure  (Appendix).

All new information is highlighted in the document.

The document is available at the AIDSinfo Web site: http://www.aidsinfo.nih.gov/guidelines/default_db2.asp?id=66

You can download guidelines or can request to receive them by e-mail or regular mail on the AIDSinfo Web site.

Your feedback is important!

The Perinatal HIV Guidelines Working Group would like to hear your feedback on the latest revisions to the "Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States." Please send your comments with the subject line "Perinatal Comments" to AIDSinfoWebmaster@aidsinfo.nih.gov by December 1, 2005.

ClinicalTrials.gov Info